Wake Forest Atrium HeartShare Clinical Center

维克森林中庭 HeartShare 临床中心

• 批准号: 10678972
• 负责人: DALANE W KITZMAN
• 金额: $ 27.47万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-10 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10678972
• 关键词: Abdomen; Acceleration; Address; Adipose tissue; Age; Aging; Aorta; Artificial Intelligence; Biological; Biological Markers; Biopsy; Blood; Blood Vessels; Body Composition; Brain; Cardiac; Clinical; Cognition; Collaborations; Complement; Consensus; Consent; Control Groups; Creativeness; DNA; Data; Development; Diabetes Mellitus; EFRAC; Educational workshop; Electrocardiogram; Electronic Health Record; Enrollment; Ensure; Evidence based treatment; Functional disorder; Funding; Future; Genetic Materials; Goals; Health; Health system; Heart; Heart Atrium; Heart failure; Heterogeneity; Hypertension; Image; Institution; International; Intervention; Lead; Leadership; Lung; Machine Learning; Magnetic Resonance Imaging; Mental Depression; Mitochondria; Monitor; Morbidity - disease rate; Muscle; Obesity; Outcome; Paper; Participant; Pathogenesis; Patient Recruitments; Patients; Phase; Phenotype; Physical activity; Plasma; Population Heterogeneity; Population Study; Prevalence; Prognosis; Protocols documentation; Qualifying; Quality of life; Recommendation; Reporting; Research Personnel; Research Priority; Resources; Sampling; Seminal; Serum; Signal Transduction; Skeletal Muscle; Specimen; Structure; Syndrome; Techniques; Testing; Thigh structure; Tissue Sample; United States National Institutes of Health; Visit; Work; actigraphy; bioinformatics tool; cardiac magnetic resonance imaging; career; clinical center; cohort; comorbidity; data repository; deep learning; design; experience; forest; frailty; gender diversity; innovation; insight; microbiome; mortality; multidisciplinary; new therapeutic target; novel; preservation; primary outcome; programs; prospective; racial diversity; randomized trial; recruit; response; retention rate; signal processing; success; therapeutic target

Project Summary Heart Failure with Preserved Ejection Fraction (HFpEF) is the most common form of HF in the US and is associated with high morbidity and mortality. However, its pathophysiology is incompletely understood, and most trials have been neutral such that few evidence-based treatments exist. In response, NIH convened 2 workshops co-led by Dr. Kitzman (PI). The highest priority research recommendation was a coordinated effort to create a large cohort of HFpEF patients and controls and perform comprehensive, deep phenotyping. This became the basis for HeartShare, whose ultimate goals are to discover novel HFpEF mechanisms, subtypes, and therapeutic targets. Our Wake Forest - Atrium HFpEF team is highly qualified to serve as a Clinical Center and make robust, over-arching contributions to HeartShare. Dr. Kitzman is internationally recognized as a thought-leader in HFpEF with a sustained track record of developing novel concepts regarding HFpEF pathogenesis, mechanisms, and outcomes and designing and conducting innovative studies to test them. His team has extensive experience in all key aspects of the HeartShare program, particularly in recruiting, retaining, and phenotyping diverse populations of HFpEF patients and controls, often significantly exceeding goals for racial and gender diversity. Our institutions have ~15,000 HFpEF clinical visits annually. In all, our team has led or helped lead recruitment and phenotyping for 69 studies, mostly NIH-sponsored, with 15,354 participants, demonstrating our ability to fulfill HeartShare recruitment and phenotyping goals. Data from these studies will be contributed to the Cohort phase of HeartShare. We will make robust contributions to HeartShare by achieving 4 Specific Aims: Aim 1) Provide ‘thought leadership’ in collaboration with the HeartShare Steering Committee; Aim 2) Contribute data, images, and stored specimens cohort phase of HeartShare from our numerous studies of HFpEF and controls, and identify and phenotype HFpEF patients and controls from the electronic health record using robust bioinformatics tools; Aim 3) Recruit, consent, enroll and follow at least 250 HFpEF patients plus controls (type and number to be determined by consensus); Aim 4) Conduct state-of- the-art deep phenotyping exams using a collaboratively determined protocol. Our phenotyping proposal is highly innovative, with advanced echo-Doppler and cardiac magnetic resonance imaging, CPET, physical activity monitoring, remote and artificial intelligence electrocardiography, sampling of skeletal muscle, adipose, blood, and microbiome, and mitochondrial energetics, and brain structure/function. Our diverse, cross- disciplinary team has the full range of complementary expertise and access to the robust resources of two large, closely affiliated health systems to ensure fulfillment of all HeartShare’s goals. We will help accelerate and optimize the program’s success with our insight, creativity, and sustained track record of collaboration, innovation, and dissemination.

项目摘要 心力衰竭伴射血分数保留(HFpEF)是美国最常见的心衰形式， 与高发病率和高死亡率有关。然而，其病理生理机制尚不完全清楚，而且 大多数试验都是中性的，因此几乎没有循证治疗方法。作为回应，美国国立卫生研究院召集了2个 由Kitzman博士(PI)共同主持的研讨会。最优先的研究建议是协调一致的努力 建立大量HFpEF患者和对照的队列，并进行全面、深入的表型分析。这 成为了HeartShare的基础，其最终目标是发现新的HFpEF机制、亚型 和治疗靶点。我们的维克森林-中庭HFpEF团队非常有资格作为临床中心 并为HeartShare做出强有力的、最重要的贡献。基茨曼博士是国际公认的 HFpEF的思想领袖，有开发关于HFpEF的新概念的持续记录 发病机制、机制和结果，并设计和进行创新的研究来测试它们。他的 团队在心脏分享计划的所有关键方面都有丰富的经验，特别是在招聘方面， 保留HFpEF患者和对照的不同人群，并对其进行表型分析，通常显著超过 实现种族和性别多样性的目标。我们的机构每年有大约15,000次HFpEF临床就诊。总而言之，我们的 团队领导或帮助领导了69项研究的招募和表型分析，其中大部分是由NIH赞助的，有15,354项研究 参与者，表明我们有能力实现心脏共享招募和表型目标。来自这些网站的数据 这些研究将被用于心脏分享的队列阶段。我们将为心脏共享做出强有力的贡献 通过实现4个具体目标：目标1)与红心共享指导合作，提供“思想领导” 委员会；目标2)来自我们的心跳共享的数据、图像和存储的样本队列阶段 大量关于HFpEF和对照组的研究，并从 使用强大的生物信息学工具的电子健康记录；目标3)招募、同意、登记和遵循至少 250名HFpEF患者和对照组(类型和数量将通过协商一致确定)；目标4)进行状态- 最先进的深度表型测试使用协作确定的方案。我们的表型建议是 高度创新，具有先进的回波多普勒和心脏磁共振成像，CPET，物理 活动监测、远程和人工智能心电图仪、骨骼肌、脂肪、 血液、微生物组、线粒体能量学和脑结构/功能。我们多样化的，交叉的- 纪律团队拥有全方位的互补专业知识，并可获得两家公司的强大资源 大型、紧密联系的健康系统，以确保实现心脏共享的所有目标。我们将帮助加速 并凭借我们的洞察力、创造力和持续的协作记录来优化计划的成功， 创新和传播。